Compare RNST & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | LQDA |
|---|---|---|
| Founded | 1904 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 1995 | 2020 |
| Metric | RNST | LQDA |
|---|---|---|
| Price | $39.86 | $52.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $43.00 | $41.00 |
| AVG Volume (30 Days) | 531.0K | ★ 929.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 0.94 | 0.52 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $31.72 | $278.87 |
| Revenue Next Year | $4.67 | $57.13 |
| P/E Ratio | $42.69 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $33.04 | $11.85 |
| 52 Week High | $42.11 | $46.67 |
| Indicator | RNST | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 81.58 |
| Support Level | $39.24 | $30.48 |
| Resistance Level | $40.60 | N/A |
| Average True Range (ATR) | 0.84 | 2.54 |
| MACD | -0.08 | 1.10 |
| Stochastic Oscillator | 40.12 | 92.14 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.